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Objectives: This study was conducted to assess the acute safety and short term efficacy of
renal sympathetic denervation (RSDN) using solid tip radiofrequency ablation (RFA) catheter
and saline irrigation through the renal guiding catheter to achieve effective denervation.
Background: RSDN using a specialized solid-tip RFA catheter has recently been demon-
strated to safely reduce systemic blood pressure in patients with refractory hypertension,
the limitation being inadequate power delivery in renal arteries. So, we used solid-tip RFA
catheter along with saline irrigation for RSDN.
Methods: Nine patients with resistant hypertension underwent CT and conventional renal
angiography, followed by bilateral or unilateral RSDN using 5F RFA catheter with saline irri-
gation through renal guiding catheter. Repeat renal angiographywas performed at the end of
the procedure. In all patients, pre- and post-procedure serum creatinine was measured.
Results: Over 1-month period: 1) the systolic/diastolic blood pressure decreased by
57 ± 20/25 ± 7.5 mm Hg; 2) all patients experienced a decrease in systolic blood pressure
of at least 36 mm Hg (range 36e98 mm Hg); 3) there was no evidence of renal artery injury
immediate post-procedure. There was no significant change in serum creatinine level.
Conclusions: This data shows the acute procedural safety and short term efficacy of RSDN
using modified externally irrigated solid tip RFA catheter.
Copyright © 2015, Cardiological Society of India. All rights reserved., Second Floor, 12th A C
, pedssachin@yahoo.co.i
ociety of India. All rightsross, 6th A Main, J P Nagar 3rd Phase, Bangalore 560102, India.
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Current therapeutic strategies for this condition are mainly
based on lifestyle interventions and pharmacological ap-
proaches. The rates of control of blood pressure and the
therapeutic efforts to prevent their sequelae however remain
unsatisfactory and additional options are required. Among
patients with hypertension, there exists a subset who are
unable to achieve adequate BP control despite the use of
multiple medications and dietary and lifestyle modifications.
These patients (termed drefractory or dresistant) are, by
common definition, receiving >3 different classes of antihy-
pertensive therapy, with one being a diuretic, and at maximal
recommended or maximal tolerated doses.1
The estimates of resistant hypertension prevalence range
from 13% to 30% among adults receiving drug treatment for
hypertension.2,3These numbers reflect a serious global health
challenge given the observation that with every 20/10-mmHg
increase in blood pressure, cardiovascular mortality doubles.4
For such patients, treatment options are few. Device or
procedure-based therapies have also been studied recently.
One such approach involves a percutaneous, catheter-based
renal sympathetic denervation procedure to disrupt renal
afferent and efferent nerves using radiofrequency ablation.4,5
There is evidence that resistant hypertension may, at least in
part, be mediated by chronic activation of the sympathetic
nervous system (SNS).6
Initial proof-of-concept studies have demonstrated both
reductions in BP and evidence of organ-specific sympathetic
denervation. Furthermore, the procedure was found to be
both simple to perform and safe.7,8 Symplicity HTN-2 which is
a randomized controlled clinical trial of renal denervation in
patients with treatment-resistant hypertension, showed a 33/
11 mm Hg reduction of 6-month office BP compared with
controls.8 Follow up of patients for 24 months in Symplicity
HTN 1 had shown that blood pressure reduction with RSDN is
durable.9 Symplicity 3 did not show a significant reduction of
systolic blood pressure in patients with resistant hyperten-
sion 6 months after renal-artery denervation as compared
with a sham control.10
During RSDN, a Symplicity catheter connected to a radio-
frequency (RF) generator is used to cause sympathetic
denervation which is achieved percutaneously through the
lumen of the main renal artery. As we do not have access to
this catheter, we used conventional 5F solid tip ablation
catheter for RSDN. We observed the inadequate power
(sometimes as low as 0e1 W) delivery and rise in local tem-
perature during RSDN. The initial clinical studies (Symplicity1
and 2) which demonstrated the proof of principle and safety of
RSDN, have surprisingly not mentioned the amount of power
delivered during renal denervation. During temperature-
controlled RF ablation, the tip temperature, tissue tempera-
ture, and lesion size are affected by the electrodeetissue
contact and cooling effects resulting from blood flow. With
good contact between catheter tip and tissue and low cooling
of the catheter tip, the target temperature can be reachedwith
little power, resulting in small lesions even though a high tip
temperature is being measured. In contrast, a low tip tem-
perature can be caused by a high level of convective cooling,
which results in higher power delivery to reach the target
temperature, yielding a larger lesion. Power deliverydetermines the size and depth of the RF lesion created.11 Ve-
locity of blood flow in renal arteries is normally fast but once
the arteries are engaged with renal guide, the flow reduces
resulting in inadequate cooling of the cathetereendothelial
surface interface. As a result adequate power is not delivered
to create a lesion in the vessel wall at the level of adventitia
where nerve endings are located. Theoretically rise in tem-
perature at cathetereendothelial surface interface can cause
endothelial injury, thrombus formation and charring. Rise in
local temperature will not allow adequate power and in turn
temperature to be delivered to the deeper tissues, thereby
creating inadequate RF lesion at adventitial layer. It can be
avoided by using irrigation tip catheter but the size of avail-
able catheters is larger than 7.5F. Manipulating larger catheter
in renal arteries may not only be difficult, but harmful. So, we
used external cooling by irrigating through the renal guiding
catheter as described below. We report here our experience
with external cooling by saline irrigation through the renal
guiding catheter using conventional solid tip radiofrequency
ablation catheters in nine patients with RH.1. Methods
Procedure was performed after obtaining written informed
consent in all patients according to the institutional guide-
lines at Narayana Hrudayalaya Hospital, Bengaluru, India.
1.1. Patient characteristics
All patients were suffering from chronic resistant hyperten-
sion (systolic BP 140 mm Hg for more than 6 months) re-
fractory to3antihypertensivemedications (including at least
one diuretic). Patients with secondary hypertension, renal
dysfunction not on dialysis and unsuitable renal artery anat-
omy (haemodynamically significant stenosis, post renal an-
gioplasty, short and smaller renal arteries) were excluded.
1.2. Baseline measurements
All patients were observed for six months on appropriate
antihypertensives to ensure that there is compliance with
medications. Serum creatinine was measured in all patients.
CT renal angiogram was done in all patients to look for renal
artery diameter, length and stenosis.
1.3. Renal sympathetic denervation
Procedure was performed under conscious sedation and
analgesia. After standard right femoral arterial access, hepa-
rin was administered to maintain ACT >250. 7F renal double
curve (RDC, Medtronic Vascular Santa Rosa, CA, USA) guiding
catheter was advanced over the 0.32 inch Terumo wire into
the abdominal aorta. Each renal artery was selectively
engaged and angiogramwas performed to study the anatomy.
Digital subtraction angiography (DSA) was performed to get a
shadow of renal arteries. Under fluoroscopic guidance 5F,
4 mm solid tip ablation catheter (St. Jude Medical, St. Paul,
Minnesota, USA) was advanced into distal renal artery (Fig. 1).
A Stockert RF generator was used to deliver RF energy in
Fig. 1 e Renal angiogram and RFA catheter in the renal artery.
Table 1 e Baseline characteristics.
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through Y connector and 20 cc leur lock syringe filled with
saline was attached to the manifold (Fig. 2). Irrigation was
started manually just before delivering RF energy, maintain-
ing sufficient saline flow to achieve 8e10 W power with tem-
perature limit of 43 C. RF energywas delivered for 30 s in each
endothelial location after adequate power (8 W) was reached,
targeting an impedance drop of 5e10 U. RFA was delivered in
thismanner at 5e6 locations (each separated by at least 5mm)
from distal to proximal, approximately in a circumferential
manner. Post-procedure angiogram was done to look for
dissection, spasm and blood flow.
1.4. Follow up
Post-procedure, all patients were being followed up for regular
office blood pressure (7 days, 1 month, 3 months, 6 months
and 1 year), and serum creatinine measurement.
1.5. Statistical analysis
Continuous variables are expressed asmean ± SD. Descriptive
statistics were applied to assess the major endpoints: 1)
change in BP, as obtained from the office blood pressure; 2)
freedom from procedural complications; and 3) freedom fromFig. 2 e RFA catheter, renal guide, manifold and saline
irrigation syringe assembly. 1 e Renal double curve guide;
2 e Y connector; 3 e 5F solid tip ablation catheter (St. Jude
Medical, St. Paul, Minnesota, USA); 4 e Manifold; 5e20 cc
syringe filled with saline used for irrigation.change in renal function, as measured by serum creatinine
levels.2. Results
2.1. Patient characteristics
This prospective, consecutive series consisted of 9 hyperten-
sive patients refractory to treatment with mean of 4.6 medi-
cations (range 3e6), including diuretic therapy. The mean age
of the patient cohort was 58.7 years (Table 1). We present re-
sults of one month follow up.
2.2. Ablation procedure
Renal angiography revealed variable number and tortuous
arterial anatomy. Despite variable anatomy, the vasculature
wasamenable toablation inonebut all patients. Therewasone
patient with ostial 60% stenosis of right renal artery; ablation
was not attempted in right renal artery to avoid the risk of
atheroembolisation and dissection. A total of 98 lesions were
delivered in this patient cohort. Overall, the total number ofn ¼ 9
Demographics
Mean age in years (SD) 58.7 (12)
Males 44.4%
Mean body mass index (SD) 27.23 (3.2)
Co-morbid conditions
Diabetes mellitus 8
Atrial fibrillation 3
Coronary artery disease 1
End stage renal disease 1
Antihypertensive drugs
Angiotensin converting enzyme inhibitor 1
Angiotensin receptor blocker 7
Beta-blocker 8
Calcium-channel blocker 6
Diuretic 9
Centrally acting antihypertensive 8
Alpha blocker 2
SD ¼ Standard Deviation.
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(range 0e7) to the left and right renal arteries, respectively
(Table 2). The mean duration of ablation was 41.1 ± 3.45 s per
lesion. During radiofrequency energy delivery, variable degree
of painwas experienced by all subjects. This discomfort lasted
only for the duration of ablation and was managed success-
fully with intravenous benzodiazepines and fentanyl.2.3. Complications
There were no major complications. One patient had signifi-
cant bradycardia during ablation on the left side and required
pulses of RF delivery to avoid severe bradycardia.2.4. Blood pressure
The mean baseline blood pressure was 193.5 ± 25 mm Hg on
4.6 ± 0.71 antihypertensive medications (range 3e6). Details of
medications are listed in Table 3. There was significant blood
pressure drop within 24 h of procedure, so that dose of at least
one medication could be reduced at discharge except in one
patientwithCKD.Averagedurationof followupwasonemonth
at the end of which mean BP was 136 ± 17.7/80.6 ± 6.4 mm Hg
indicating a change of57± 20mmHg in systolic BP (range36
to 98 mm Hg; p < 0.0002) and 25 ± 7.5 mm Hg (range 12 to
40 mmHg; p < 0.0002) in diastolic BP. As there was sustained
drop in blood pressure at one month follow up, at least one
medication was stopped (centrally acting drugs) and dosage of
other medicines were reduced as necessary.2.5. Additional benefits
one patient with atrial fibrillation had recurrent pulmonary
edema requiring multiple hospitalizations. After RSDN, her
ventricular rate was better controlled with similar medica-
tions and no hospitalization for pulmonary edema was
required at the end of 3 months follow up period.2.6. Serum creatinine
Therewas no change in serumcreatinine levels at 7 days and 1
month follow up establishing the safety of the procedure on
renal function.Table 2 e Radiofrequency ablation parameters.
Patient No. No of lesions Ablation duration
Mean (SD)LRA RRA
1 5 5 40 (6)
2 10a 5 45 (5.2)
3 5 5 35 (4.8)
4 6 7 45 (7)
5 5 0 45 (5.4)
6 5 6 40 (4)
7 5 5 45 (5.2)
8 5 7 35 (4)
9 5 7 40 (5.2)
a Had bifurcation of renal artery. Five lesions were delivered into each. L3. Discussion
Our study, in a small group of patients with drug resistant
systemic hypertension, demonstrated that renal sympathetic
denervation is safe and effective, using modified externally
irrigated solid tip RFA catheter. There were no acute or sub-
acute major complications. One patient had significant
bradycardia during ablation which returned to normal heart
rate after stopping ablation. There was significant (136 ± 17.7/
80.6 ± 6.4 mm Hg) reduction in office blood pressure in all
patients at one month follow up.
First in human clinical studies have demonstrated that
RSDN can significantly decrease BP in patients with resistant
hypertension using specially designed RFA catheters.6,7 Sym-
plicity HTN-1, was a nonrandomized study employing this
specialized RFA catheter in 45 drug-resistant hypertensive
patients; the baseline office BP (177 ± 20 mm Hg/101 ± 15 mm
Hg, on 4.7 antihypertensivemedications) decreased by amean
of 27/17mmHg at 1 year. Therewas concurrent 47% reduction
in renal noradrenaline spill over and a 66% decrease inmuscle
SNS activity. Most importantly, this favorable BP decreasewas
reported to be maintained over 2 years.7,9
Symplicity HTN-2 also evaluated RSDN in patients with
refractory hypertension and this was a randomized clinical
trial. In this study of 106 randomized patients, the 6-month
office BP in the denervation group decreased by 32/12 mm
Hg (baseline of 178/96 mm Hg, p ¼ 0.0001), whereas they did
not differ from baseline in the control group (change of 1/
0 mmHg, baseline 178/97 mmHg, p ¼ NS). From an individual
perspective, 41 of 49 patients (84%) in the renal denervation
group experienced a 6-month BP decrease of 10 mm Hg.
Importantly, no serious procedure-related adverse events
were noted.8
Symplicity 310 was randomized trial of renal denervation
with sham controlled arm. A total of 535 patients underwent
randomization. The mean (±SD) change in systolic blood
pressure at 6 months was 14.13 ± 23.93 mm Hg in the
denervation group as compared with11.74 ± 25.94 mmHg in
the sham-procedure group (p < 0.001 for both comparisons of
the change from baseline), for a difference of 2.39 mm Hg
(95% confidence interval [CI], 6.89 to 2.12; p ¼ 0.26 for supe-
riority with a margin of 5 mm Hg). The change in 24-
h ambulatory systolic blood pressure was 6.75 ± 15.11 mm
Hg in the denervation group and 4.79 ± 17.25 mm Hg in thein sec Energy delivered
(in Watts)
Maximum temperature
(Degrees)
8 40
10 39
10 37
10 41
8 38
10 36
10 40
10 38
8 42
RA ¼ Left renal artery, RRA ¼ Right renal artery.
Table 3 e Comparison of pre and post renal sympathetic denervation blood pressure values and antihypertensive drug
requirements.
Patient No. Baseline
SBP
Post RSDN
SBP
Baseline
DBP
Post RSDN
DBP
Pre RSDN
No of drugs
Post RSDN
No of drugs
1 148 112 98 76 4 1
2 150 110 92 72 3 2
3 206 150 104 80 4 1
4 170 128 92 80 5 4
5 210 130 110 80 6 5
6 216 168 140 100 5 3
7 224 148 108 90 4 3
8 218 120 110 70 5 3
9 200 158 100 78 5 4
SBP ¼ Systolic Blood Pressure; RSDN ¼ Renal Sympathetic Denervation; DBP ¼ Diastolic Blood Pressure.
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CI,4.97 to 1.06; p¼ 0.98 for superiority with amargin of 2mm
Hg). After Symplicity 3 enthusiasm for renal denervation has
reduced. Reasons for the failure of the trial need to be further
analyzed.
3.1. Radiofrequency ablation biophysics
Specialized catheters used in Symplicity HTN-1 and Sym-
plicity HTN-2 trials were conventional solid tip catheters. At
steady state, the lesion size is proportional to the temperature
measured at the interface between the tissue and the elec-
trode as well as to the RF power amplitude. By using higher
powers and achieving higher tissue temperatures, the lesion
size can be increased. However, once the peak tissue tem-
perature exceeds the threshold of 100 C, boiling of the plasma
at the electrodeetissue interface can ensue. When boiling
occurs, denatured serum proteins and charred tissue form a
thin film that adhere to the electrode, forming an electrically
insulating coagulum, which is accompanied by a sudden in-
crease in electrical impedance preventing further current flow
into the tissue and further heating.12,13
This rise in impedance can be prevented by convective
cooling. The higher magnitude of power increases the depth
of direct resistive heating and, in turn, increases the radius of
the effective heat source. In addition, higher temperatures are
achieved 3e4 mm below the surface, and the entire radial
temperature curve is shifted to a higher temperature over
greater tissue depths.
Electrode-tip cooling can be achieved passively or actively.
Passive tip cooling occurs when the circulating blood flow
cools the mass of the ablation electrode and cools the elec-
trodeetissue interface. Active tip cooling can be realized with
a closed or open perfused-tip system. In each case, circulating
saline from an infusion pump actively cools the electrode tip
and the opposing design infuses the saline through weep
holes in the electrode into the bloodstream. Both designs are
effective and result in larger lesions and greater procedure
efficacy than standard RF catheter ablation. Theoretical ad-
vantages and disadvantages of open perfusion versus closed
perfusion catheter designs are claimed by device manufac-
turers and their spokes people, but the lesions produced and
the clinical efficacy and safety profiles of these competing
designs are very comparable.14e17The tip cooling or perfusion has the apparent advantage of
reducing the prevalence of coagulum and char formation.
These advantages to saline irrigation are significant enough
that most left-sided cardiac ablations are now performed
using irrigated ablation catheters.18
We have noticed that there was abrupt impedance rise and
inadequate power delivery during RSDN using 5F, 4 mm solid
tip catheter in spite of being high blood flow in renal arteries.
Effective cooling of ablation catheter may be prevented by the
reduced blood flow after engaging renal arteries with RDC
guiding catheter. Available irrigation tip catheters are of larger
size making them inconvenient to use and difficult to
manipulate in the renal arteries. So, we used saline irrigation
manually through the renal guiding catheter and the power
delivered is likely to be higher than non-irrigated solid tip
specialized catheters used in trials.
There is a small prospective study (n ¼ 10)19 which
demonstrated the safety and efficacy of irrigation tip ablation
in RSDN. Renal angiography at 3 months showed no stenosis.
There was better drop in BP in this study compared to Sym-
plicity HTN trials, the BP decrease from a baseline of 158 ± 16/
88 ± 15 mm Hg was modest at 1 month (6/4 mm Hg,
p ¼ 0.002/p ¼ 0.02), but decreased more significantly at 3
months (22/13 mm Hg, p ¼ 0.0001/p ¼ 0.0001). These blood
pressure changes were sustained at 6 months (21/11 mm
Hg, p ¼ 0.003/p ¼ 0.005). The magnitude of BP reduction
observed between baseline and 6 months in Simplicity HTN-2
(11/7 vs. 3/1 mm Hg for the RSDN and controls,
respectively) was directionally consistent, but numerically
less than observed in this study (21/11 mm Hg).
SYMPLICITY HTN-3 trial, randomized, sham-controlled,
blinded trial did not show a benefit of renal-artery denerva-
tion with respect to either of the efficacy end points for which
the study was powered (reduction in office or ambulatory
systolic blood pressure at 6 months).10 This study lowered the
enthusiasm for a promising breakthrough therapy in resistant
hypertension. This led to the analysis of SYMPLICITY HTN-3
trial data. There is a learning curve for any procedure before
getting optimal results. The enthusiasm to enroll more pa-
tients in a short duration of time increased the number of
inexperienced operators. In this trial, procedure was per-
formed by inexperienced operators as half of the operators
performed only two procedures and 31% performed only one
RDN procedure during the trial. Patients receiving more
i n d i a n h e a r t j o u r n a l 6 7 ( 2 0 1 5 ) 2 0 7e2 1 3212ablation lesions showed greater reductions in blood pressure
implying better denervation with more ablation.20 Notching
on angiography has been mentioned as confirmation of en-
ergy delivery by catheter. Notching can happen because of
endothelial injury and spasm of vessel rather than trans
mural energy delivery. As discussed above effective denerva-
tion needs adequate power delivery, which is unlikely to
happen with solid tip catheter used in this trial. There is no
data on the power delivered and impedance drop with each
lesion. The set power needs to be delivered to achieve
denervation. In our experience, power delivery cannot be
achieved with solid tip catheter. We need to have irrigated tip
catheters to ensure adequate power delivery and effective
denervation. So, SYMPLICITY HTN-3 trial results need to be
analyzed carefully before disregarding RSDN. There is a role
for RSDN even in the event of failure of this major trial to
demonstrate efficacy of renal denervation.
In our study, the magnitude of blood pressure reduction
was higher compared to Symplicity trials and other studies.
Blood pressure reduction was observed the very next day of
RSDN. We had to reduce either the number or the dose of
antihypertensivemedications on discharge. Themagnitude of
blood pressure reduction in yet another study from Indian
subcontinent is also more than (43.5/21 mm Hg)21 simplicity
trials.
The reason for such a differencemay be related to: 1) Racial
difference 2) the ability of saline-irrigation to create better,
deeper RF lesions and hence better denervation and 3) the
larger electrode of the irrigated RFA catheter might allow for
greater coverage of the vessel perimeter, thereby maximizing
the effect of RSDN procedure. This might also explain why all
patients in our series exhibited BP dropdas compared to a 14%
and 16% non-responder rate in Symplicity HTN-1 and 2,
respectively.4,6 However, smaller number of patients in the
present study and the absence of a control group, both
mandate that we consider these data as merely hypothesis
generating and understand that it will ultimately require
randomized clinical trial testing.4. Limitations
An important limitation of this study is that it is not a placebo
controlled one. The blood pressure changes post RSDN is
significant, which is unlikely to be related to pressure lowering
biofeedback effect. We have not recorded ABPM at 1 month
which is a second limitation. Yet another limitation is that we
have not measured pre and post RSDN catecholamine levels.4.1. Conclusions
RSDN can be performed safely and effectively in patients with
resistant hypertension, using an off-the-label modified saline
irrigated RFA catheter. This study experience provides the
scientific basis for future randomized controlled trials to
assess the safety and efficacy of RSDN with irrigated tip
catheter targeting impedance drop, in refractory hypertensive
patients in a placebo-controlled (sham procedure) blinded
manner.Conflicts of interest
All authors have none to declare.
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